Elevated Urine Creatinine with Normal Urine Albumin-to-Creatinine Ratio

Understanding the Clinical Scenario

The American College of Physicians and the American Diabetes Association recommend that an isolated elevated urine creatinine with a normal urine albumin-to-creatinine ratio (<30 mg/g) does not indicate kidney damage and requires no specific intervention beyond standard annual screening if the patient has diabetes or other CKD risk factors 1, 2
The urine albumin-to-creatinine ratio is the preferred screening test for chronic kidney disease, where the creatinine measurement serves solely as a correction factor to normalize for urine concentration and hydration status—not as an independent marker of kidney function, as stated by the National Kidney Foundation 1, 3

A urine albumin-to-creatinine ratio <30 mg/g creatinine is definitively normal and indicates no evidence of kidney damage, regardless of the absolute urine creatinine value, according to the American Diabetes Association 1, 2, 3
The normal range is <30 mg/g creatinine, moderately increased albuminuria is 30-299 mg/g creatinine, and severely increased albuminuria is ≥300 mg/g creatinine, as defined by the National Kidney Foundation 1, 2, 3

For patients with diabetes or hypertension, the American Diabetes Association recommends continuing annual urine albumin-to-creatinine ratio screening as standard preventive care, not a response to the current result 2, 3, 4
For patients with type 1 diabetes, screening should start 5 years after diagnosis, and for type 2 diabetes, screening should start at diagnosis, as recommended by the American Diabetes Association 2
The American Heart Association recommends measuring serum creatinine and calculating eGFR annually to assess kidney function, since reduced eGFR without albuminuria occurs in 30-50% of diabetic CKD cases 4, 3

Nephrology referral is not indicated for a normal urine albumin-to-creatinine ratio, but becomes appropriate when eGFR <30 mL/min/1.73 m², urine albumin-to-creatinine ratio ≥300 mg/g creatinine (persistently), or rapidly declining eGFR (>5 mL/min/1.73 m² per year), as stated by the National Kidney Foundation 3, 4, 5

The American Diabetes Association recommends that the urine albumin-to-creatinine ratio (UACR) stratifies patients into three distinct risk categories that determine both cardiovascular and kidney disease progression risk, with elevated levels associated with increased risk: Normal to mildly increased (<30 mg/g creatinine), Moderately increased albuminuria (30-299 mg/g creatinine), and Severely increased albuminuria (≥300 mg/g creatinine) 6
The American College of Cardiology recommends UACR ≥30 mg/g as an indication for ACE inhibitor or ARB therapy as first-line treatment to reduce progressive kidney disease risk, regardless of blood pressure control, with a strength of evidence of Grade A for UACR ≥300 mg/g and Grade B for UACR 30-299 mg/g 7, 8

The American Diabetes Association recommends annual UACR screening for all patients with type 2 diabetes from diagnosis, patients with type 1 diabetes after 5 years duration, and all diabetic patients with comorbid hypertension, with an increase in monitoring frequency to every 6 months for patients with eGFR <60 mL/min/1.73 m² or UACR >30 mg/g 6, 9

A sustained ≥30% reduction in UACR is an accepted surrogate marker of slowed kidney disease progression, with the treatment goal being to reduce UACR by at least 30-50% and ideally achieve <30 mg/g, according to the American Diabetes Association 6

The National Kidney Foundation recommends that both eGFR and UACR are required to properly stage kidney disease, with serum creatinine and eGFR measured at least annually in conjunction with UACR screening, and monitoring of serum creatinine/eGFR and potassium at least annually for patients on ACE inhibitors, ARBs, or diuretics 7, 8